[go: up one dir, main page]

NO954437D0 - Preparater og metoder for reparasjon og forhindring av fibrotiske skader - Google Patents

Preparater og metoder for reparasjon og forhindring av fibrotiske skader

Info

Publication number
NO954437D0
NO954437D0 NO954437A NO954437A NO954437D0 NO 954437 D0 NO954437 D0 NO 954437D0 NO 954437 A NO954437 A NO 954437A NO 954437 A NO954437 A NO 954437A NO 954437 D0 NO954437 D0 NO 954437D0
Authority
NO
Norway
Prior art keywords
fibrotic
prevention
preparations
repair
methods
Prior art date
Application number
NO954437A
Other languages
English (en)
Other versions
NO954437L (no
NO308507B1 (no
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Publication of NO954437L publication Critical patent/NO954437L/no
Publication of NO954437D0 publication Critical patent/NO954437D0/no
Publication of NO308507B1 publication Critical patent/NO308507B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
NO954437A 1993-05-07 1995-11-06 Anvendelse av pyridoner for fremstilling av et farmasøytisk preparat for reparasjon og forhindring av fibrotiske skader NO308507B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5921493A 1993-05-07 1993-05-07
US6483193A 1993-05-19 1993-05-19
PCT/US1994/005156 WO1994026249A1 (en) 1993-05-07 1994-05-09 Compositions and methods for reparation and prevention of fibrotic lesions

Publications (3)

Publication Number Publication Date
NO954437L NO954437L (no) 1995-11-06
NO954437D0 true NO954437D0 (no) 1995-11-06
NO308507B1 NO308507B1 (no) 2000-09-25

Family

ID=26738503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954437A NO308507B1 (no) 1993-05-07 1995-11-06 Anvendelse av pyridoner for fremstilling av et farmasøytisk preparat for reparasjon og forhindring av fibrotiske skader

Country Status (10)

Country Link
EP (1) EP0702551B1 (no)
JP (1) JPH08510251A (no)
AT (1) ATE224712T1 (no)
AU (1) AU687816B2 (no)
BR (1) BR9406461A (no)
CA (1) CA2161648A1 (no)
DE (1) DE69431433T2 (no)
ES (1) ES2183839T3 (no)
NO (1) NO308507B1 (no)
WO (1) WO1994026249A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
WO1996027374A1 (en) * 1995-03-03 1996-09-12 Margolin Solomon B Treatment of cytokine growth factor caused disorders
EP0831796A1 (en) * 1995-06-07 1998-04-01 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors
JP2002522462A (ja) * 1998-08-13 2002-07-23 ハダシット・メディカル・リサーチ・サービシイズ・アンド・ディベロプメント・カンパニー・リミテッド 組織外傷に関連した病原プロセスの阻害
AU1226099A (en) 1998-09-18 2000-04-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
JP4077320B2 (ja) 2001-01-29 2008-04-16 塩野義製薬株式会社 ５−メチル−１−フェニル−２−（１ｈ）−ピリドンを有効成分として含有する医薬製剤
BR0207310A (pt) * 2001-12-18 2004-08-17 Mondobiotech Sa Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2004073680A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. 液滴分散型軟膏剤
US20060198823A1 (en) * 2003-04-04 2006-09-07 Blatt Lawrence M Compositions and methods for treating viral infections
CA2545813C (en) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
PL2029572T3 (pl) * 2006-06-05 2011-05-31 Novartis Ag Związki organiczne
JP5213852B2 (ja) 2006-06-15 2013-06-19 シャンハイ ゲノミックス インク 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009052630A1 (en) 2007-10-26 2009-04-30 Pacific Therapeutics Ltd. Compositions and methods for treating fibroproliferative disorders
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions

Also Published As

Publication number Publication date
EP0702551A1 (en) 1996-03-27
BR9406461A (pt) 1996-01-30
AU687816B2 (en) 1998-03-05
EP0702551B1 (en) 2002-09-25
ES2183839T3 (es) 2003-04-01
AU6829194A (en) 1994-12-12
DE69431433D1 (de) 2002-10-31
ATE224712T1 (de) 2002-10-15
CA2161648A1 (en) 1994-11-24
WO1994026249A1 (en) 1994-11-24
NO954437L (no) 1995-11-06
DE69431433T2 (de) 2003-12-04
EP0702551A4 (en) 1997-08-20
NO308507B1 (no) 2000-09-25
JPH08510251A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
NO954437L (no) Preparater og metoder for reparasjon og forhindring av fibrotiske skader
IL99676A0 (en) Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines or piperazines,and compositions and methods of use thereof
FI925342A (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
MY112102A (en) Therapeutic heterocycles.
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
DK0503440T3 (da) Sumatriptanholdige lægemidler
IL94990A0 (en) Pharmaceutical compositions for the prophylaxis and/or treatment of prostatic diseases
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
ZA969621B (en) Therapeutic compounds
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
YU6196A (sh) Transdermalna flasterska formulacija
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
BG105342A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
TR200103144T2 (tr) Yeni bileşikler
BR0017367A (pt) Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica
FR2688504B1 (fr) Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
FR2689891B3 (fr) Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.